Nasdaq:BVS
Bioventus Inc.
Bioventus provides innovative bone graft substitute solutions and orthopedic reconstruction tools to address complex joint repair needs in the US market.
Key Metrics
Investment Thesis
Bull Case
The return to profitability and positive cash flow generation indicates successful execution of the company's strategic turnaround plan following years of losses. Investors may benefit from the proprietary nature of their bone graft technology which creates a sustainable revenue stream with potential for new product launches.
Bear Case
Despite recent profitability, the company carries significant long-term debt of $279M which poses a substantial interest rate risk in a high-cost capital environment. The history of consecutive annual losses prior to 2025 suggests underlying business challenges that could recur if competitive pressures or regulatory headwinds emerge.
About Bioventus Inc.
Bioventus Inc. is a medical device company specializing in orthopedic reconstruction solutions, primarily serving the United States market with its proprietary bone graft substitutes and surgical instruments. The company focuses on treating complex joint conditions by providing advanced materials that replace lost bone tissue during reconstructive procedures. Key products include their branded allografts which are critical for spinal and extremity surgeries across various hospital systems.
Analysis
Management Discussion
The company achieved a significant turnaround in 2025, reporting positive net income of $27.3M after years of losses, driven by robust revenue growth that reached $568.1M compared to $512.1M in 2022. Operating cash flow of $74.7M demonstrates improved operational efficiency despite a substantial increase in operating expenses to $334.2M as the company invested in market expansion.
Industry Overview
The orthopedic medical device industry is experiencing steady growth driven by an aging population and increasing prevalence of joint injuries requiring reconstruction procedures. Market consolidation is occurring as larger companies acquire specialized manufacturers, creating opportunities for focused players like Bioventus with proprietary technologies.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $512.1M | $512.3M | $573.3M | $568.1M |
| Cost of Revenue | $181.0M | $184.2M | $185.1M | $179.9M |
| Gross Profit | $331.1M | $328.2M | $388.2M | $388.2M |
| Operating Expenses | $582.1M | $409.9M | $400.2M | $334.2M |
| Operating Income | $-251.0M | $-81.7M | $-12.0M | $54.0M |
| R&D | $25.9M | $13.4M | $13.6M | $12.1M |
| G&A | $332.6M | $303.9M | $340.9M | $314.0M |
| Stock-Based Comp | $17.6M | $2.7M | $10.1M | $12.7M |
| D&A | $66.8M | $57.4M | $49.6M | $47.0M |
| Depreciation | $5.8M | $12.1M | $10.5M | $8.0M |
| Amortization | $67.0M | $45.2M | $39.0M | $39.0M |
| Other OpEx | $223.6M | $92.6M | $45.7M | $8.0M |
| Non-Operating Income | $-12.9M | $-39.4M | $-37.1M | $-28.3M |
| Pre-Tax Income | $-263.9M | $-121.1M | $-49.1M | $25.7M |
| Income Tax | $-50.5M | $85.0K | $-5.3M | $-1.6M |
| Continuing Ops | $-213.4M | $-121.2M | $-43.8M | $27.3M |
| Discontinued Ops | $0 | $-74.4M | $0 | $0 |
| Net Income | $-213.4M | $-195.6M | $-43.8M | $27.3M |
| Minority Interest | $-54.7M | $0 | $0 | $0 |
| Net to Common | $-158.7M | $-195.6M | $-43.8M | $27.3M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $272.6M | $268.0M | $275.6M | $272.8M |
| Cash & Equivalents | $31.8M | $37.0M | $41.6M | $51.2M |
| Accounts Receivable | $136.6M | $122.8M | $127.4M | $128.3M |
| Inventory | $85.4M | $91.3M | $92.5M | $82.2M |
| Prepaid Expenses | $18.7M | $16.9M | $14.2M | $11.1M |
| Other Current Assets | $23.0K | $0 | $0 | $0 |
| Long-Term Assets | $1.10B | $542.9M | $452.3M | $410.7M |
| PP&E (Net) | $27.6M | — | — | — |
| Intangibles | $1.04B | $482.4M | $404.7M | $368.4M |
| Goodwill | $13.8M | $7.5M | $7.5M | $7.5M |
| Operating Leases | $17.3M | $13.4M | $6.5M | $5.1M |
| LT Investments | $2.6M | $3.1M | $1.9M | $2.3M |
| Other LT Assets | $0 | $36.6M | $31.8M | $27.4M |
| Total Assets | $1.37B | $810.9M | $728.0M | $683.6M |
| Current Liabilities | $304.0M | $175.5M | $210.4M | $160.4M |
| Accounts Payable | $37.5M | $23.0M | $23.7M | $10.9M |
| Current Debt | $33.1M | $27.8M | $27.3M | $15.0M |
| Current Leases | $3.7M | $4.1M | $3.1M | $3.3M |
| Deferred Revenue | $2.9M | $2.3M | $1.7M | $955.0K |
| Other Current Liab | $114.8M | $-1.6M | $18.7M | $-48.0K |
| Long-Term Liabilities | $728.3M | $414.3M | $332.0M | $294.7M |
| Long-Term Debt | $385.0M | $367.0M | $308.3M | $279.0M |
| LT Operating Leases | $14.8M | $10.6M | $6.9M | $4.5M |
| Other LT Liab | $328.5M | $36.7M | $16.7M | $11.3M |
| Total Liabilities | $1.03B | $589.8M | $542.4M | $455.1M |
| Shareholders' Equity | $340.3M | $221.1M | $185.6M | $228.4M |
| Paid-In Capital | $481.9M | $494.3M | $505.5M | $520.9M |
| Retained Earnings | $-165.3M | $-321.5M | $-355.1M | $-334.9M |
| AOCI | $-110.0K | $794.0K | $-2.6M | $-1.9M |
| Total L&E | $1.37B | $810.9M | $728.0M | $683.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-213.4M | $-195.6M | $-43.8M | $27.3M |
| Non-Cash Adjustments | $163.5M | $218.3M | $35.2M | $73.2M |
| Working Capital Changes | $36.4M | $-7.4M | $47.5M | $-25.8M |
| Cash from Operations | $-13.5M | $15.3M | $38.8M | $74.7M |
| Capital Expenditures | $10.0M | $7.4M | $1.0M | $2.6M |
| Cash from Investing | $-116.4M | $15.8M | $23.0M | $-3.2M |
| Cash from Financing | $62.1M | $-26.7M | $-54.6M | $-62.1M |
| FX Effect | $521.0K | $629.0K | $-2.6M | $371.0K |
| Net Change in Cash | $-67.4M | $5.1M | $4.6M | $9.7M |
| Beginning Cash | $99.2M | $31.8M | $37.0M | $41.6M |
| Ending Cash | $31.8M | $37.0M | $41.6M | $51.2M |
Frequently Asked Questions
How does Bioventus Inc. make money?
Revenue is generated primarily through the sale of proprietary bone graft substitutes, surgical instruments, and related orthopedic reconstruction services. The company operates across multiple procedural areas including spine, extremity, and craniofacial reconstruction markets.
What are the main risks for BVS?
Regulatory approval delays by the FDA could impact the commercialization of new product candidates or extensions of existing indications. The medical device sector faces intense pricing pressure from payers and government programs which could compress profit margins significantly. High levels of debt relative to equity may limit financial flexibility during periods of reduced revenue growth or economic downturns.
What is BVS's competitive advantage?
Bioventus holds exclusive or licensed intellectual property rights to its unique porous calcium sulfate and synthetic composite graft materials that promote faster bone healing. The company has established strong relationships with leading orthopedic surgeons and hospital systems through its specialized training programs and direct sales force.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.